Terms: = Kidney tumors AND HLA-A, P01892, 3105, ENSG00000206503, P16188, P30447, P13746, P04439
74 results:
1. Risk assessment of cancer patients based on HLA-I alleles, neobinders and expression of cytokines.
Dhall A; Patiyal S; Kaur H; Raghava GPS
Comput Biol Med; 2023 Dec; 167():107594. PubMed ID: 37918263
[TBL] [Abstract] [Full Text] [Related]
2. Proteogenomics Reveal the Overexpression of HLA-I in Cancer.
Wang Y; Fenyö D
J Proteome Res; 2023 Nov; 22(11):3625-3639. PubMed ID: 37857377
[TBL] [Abstract] [Full Text] [Related]
3. High throughput single cell long-read sequencing analyses of same-cell genotypes and phenotypes in human tumors.
Shiau CK; Lu L; Kieser R; Fukumura K; Pan T; Lin HY; Yang J; Tong EL; Lee G; Yan Y; Huse JT; Gao R
Nat Commun; 2023 Jul; 14(1):4124. PubMed ID: 37433798
[TBL] [Abstract] [Full Text] [Related]
4. Phase I/II study of multipeptide cancer vaccine IMA901 after single-dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long-term follow up.
Hongo F; Ueda T; Takaha N; Tamada S; Nakatani T; Miki T; Ukimura O
Int J Urol; 2023 Feb; 30(2):176-180. PubMed ID: 36305687
[TBL] [Abstract] [Full Text] [Related]
5. Conditional Survival of Patients With Extracranial Oligometastatic Treated With Stereotactic Body Radiation Therapy: An International Consortium Study.
Chen H; Badellino S; Biswas T; Dagan R; Erler D; Foote M; Poon I; Redmond KJ; Ricardi U; Sahgal A; Louie AV
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):902-909. PubMed ID: 35753554
[TBL] [Abstract] [Full Text] [Related]
6. A promising Prognostic risk model for advanced renal cell carcinoma (RCC) with immune-related genes.
Cao P; Wu JY; Zhang JD; Sun ZJ; Zheng X; Yu BZ; Cao HY; Zhang FL; Gao ZH; Wang W
BMC Cancer; 2022 Jun; 22(1):691. PubMed ID: 35739510
[TBL] [Abstract] [Full Text] [Related]
7. hla-a*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.
Naranbhai V; Viard M; Dean M; Groha S; Braun DA; Labaki C; Shukla SA; Yuki Y; Shah P; Chin K; Wind-Rotolo M; Mu XJ; Robbins PB; Gusev A; Choueiri TK; Gulley JL; Carrington M
Lancet Oncol; 2022 Jan; 23(1):172-184. PubMed ID: 34895481
[TBL] [Abstract] [Full Text] [Related]
8. Cellular and Humoral Immune Responses Induced by an HLA Class I-restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer.
Nishida S; Morimoto S; Oji Y; Morita S; Shirakata T; Enomoto T; Tsuboi A; Ueda Y; Yoshino K; Shouq A; Kanegae M; Ohno S; Fujiki F; Nakajima H; Nakae Y; Nakata J; Hosen N; Kumanogoh A; Oka Y; Kimura T; Sugiyama H
J Immunother; 2022 Jan; 45(1):56-66. PubMed ID: 34874330
[TBL] [Abstract] [Full Text] [Related]
9. Effect of HLA genotype on intravesical recurrence after bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer.
Kobayashi M; Fujiyama N; Tanegashima T; Narita S; Yamamoto Y; Fujimoto N; Ueda S; Takeuchi A; Numakura K; Habuchi T; Matsuyama H; Eto M; Shiota M
Cancer Immunol Immunother; 2022 Mar; 71(3):727-736. PubMed ID: 34379177
[TBL] [Abstract] [Full Text] [Related]
10. HLA-DR and CD74 Expression and the Immune Microenvironment in Renal Cell Carcinoma.
Miura Y; Anami T; Yatsuda J; Motoshima T; Oka S; Suyama K; Inoshita N; Kinowaki K; Urakami S; Kamba T; Komohara Y
Anticancer Res; 2021 Jun; 41(6):2841-2848. PubMed ID: 34083274
[TBL] [Abstract] [Full Text] [Related]
11. Association of HLA mismatch and MTOR inhibitor regimens with malignancy and mortality after kidney transplantation.
Santos AH; Chen C; Leghrouz MA; Bueno EP; Lee JJ; Wen X
Transpl Immunol; 2021 Jun; 66():101391. PubMed ID: 33838299
[TBL] [Abstract] [Full Text] [Related]
12. miRCoop: Identifying Cooperating miRNAs via Kernel Based Interaction Tests.
Olgun G; Tastan O
IEEE/ACM Trans Comput Biol Bioinform; 2022; 19(3):1760-1771. PubMed ID: 33382660
[TBL] [Abstract] [Full Text] [Related]
13. Impact of mature dendritic cells pulsed with a novel WT1 helper peptide on the induction of HLA‑A2‑restricted WT1‑reactive CD8+ T cells.
Kan S; Bito T; Shimabuku M; Taguchi J; Ohkusa T; Shimodaira S; Sugiyama H; Koido S
Int J Oncol; 2020 Oct; 57(4):1047-1056. PubMed ID: 32945369
[TBL] [Abstract] [Full Text] [Related]
14. The Antitumor Activity of TCR-Mimic Antibody-Drug Conjugates (TCRm-ADCs) Targeting the Intracellular Wilms Tumor 1 (WT1) Oncoprotein.
Shen Y; Li YM; Zhou JJ; Zhou Z; Xu YC; Zhao WB; Chen SQ
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31408937
[TBL] [Abstract] [Full Text] [Related]
15. HLA alleles in renal transplant recipients with nonmelanoma skin cancer in southeastern Brazil.
Rogel CS; Souza-Santana FC; Marcos EVC; Ogawa MM; Basso G; Tomimori J
An Bras Dermatol; 2019 Jul; 94(3):287-292. PubMed ID: 31365656
[TBL] [Abstract] [Full Text] [Related]
16. Association of HLA Antigen Mismatch With Risk of Developing Skin Cancer After Solid-Organ Transplant.
Gao Y; Twigg AR; Hirose R; Roll GR; Nowacki AS; Maytin EV; Vidimos AT; Rajalingam R; Arron ST
JAMA Dermatol; 2019 Mar; 155(3):307-314. PubMed ID: 30673077
[TBL] [Abstract] [Full Text] [Related]
17. Clinicopathologic Features of a Series of Primary Renal CIC-rearranged Sarcomas With Comprehensive Molecular Analysis.
Mangray S; Kelly DR; LeGuellec S; Fridman E; Aggarwal S; Shago M; Matoso A; Madison R; Pramanik S; Zhong S; Li R; Lombardo KA; Cramer S; Pressey J; Ross JS; Corona RJ; Bratslavsky G; Argani P; Coindre JM; Somers GR; Ali SM; Yakirevich E
Am J Surg Pathol; 2018 Oct; 42(10):1360-1369. PubMed ID: 29901569
[TBL] [Abstract] [Full Text] [Related]
18. Differences in the frequencies of HLA-class I and II alleles between German patients with renal cell carcinoma and healthy controls.
Goebel S; Kehlen A; Bluemke K; Altermann W; Schlaf G; Fischer K; Fornara P; Wullich B; Wach S; Taubert H
Cancer Immunol Immunother; 2017 May; 66(5):565-571. PubMed ID: 28184970
[TBL] [Abstract] [Full Text] [Related]
19. Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma.
Obara W; Karashima T; Takeda K; Kato R; Kato Y; Kanehira M; Takata R; Inoue K; Katagiri T; Shuin T; Nakamura Y; Fujioka T
Cancer Immunol Immunother; 2017 Jan; 66(1):17-24. PubMed ID: 27757561
[TBL] [Abstract] [Full Text] [Related]
20. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Rini BI; Stenzl A; Zdrojowy R; Kogan M; Shkolnik M; Oudard S; Weikert S; Bracarda S; Crabb SJ; Bedke J; Ludwig J; Maurer D; Mendrzyk R; Wagner C; Mahr A; Fritsche J; Weinschenk T; Walter S; Kirner A; Singh-Jasuja H; Reinhardt C; Eisen T
Lancet Oncol; 2016 Nov; 17(11):1599-1611. PubMed ID: 27720136
[TBL] [Abstract] [Full Text] [Related]
[Next]
